Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that the concentration-time profile of raltegravir is different
in cells than that in plasma. Intracellular raltegravir concentrations may be higher and its
half-life longer than in plasma. This may explain the efficacy of raltegravir despite
variable plasma concentrations.
Phase:
Phase 1
Details
Lead Sponsor:
Changi General Hospital
Collaborators:
Merck Sharp & Dohme Corp. National University Hospital, Singapore